Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics (SRNE), announced that shares of its common stock will trade on the Nasdaq Capital Market on Friday, November 11, under the ticker symbol "SCLX". Scilex’s trading debut comes after the completion of its business combination with Vickers Vantage Corp. I, a special purpose acquisition company. The combined company now operates as Scilex Holding Company. Henry Ji, Ph.D., Executive Chairman of Scilex and Chairman and CEO of Sorrento, said: "This is an extremely exciting moment for the Scilex team. Ringing the opening bell at Nasdaq is indicative of our team’s hard work and celebration of our continued growth. I am confident and excited for Scilex’s future growth and journey ahead."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SRNE:
- Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), Debuts on Nasdaq Under Ticker “SCLX”
- Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business Combination
- Sorrento Therapeutics options imply 10.6% move in share price post-earnings